Relmada Therapeutics (RLMD) Other Working Capital Changes (2016 - 2025)
Relmada Therapeutics (RLMD) posted quarterly Other Working Capital Changes of -$6178.0 for Q3 2016, down 119.35% quarter-over-quarter from $31929.0 in Q2 2016.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Other Working Capital Changes (2016 - 2025) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Other Working Capital Changes for 6 consecutive years, with $7500.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Working Capital Changes rose 101.07% year-over-year to $7500.0; the TTM figure through Dec 2025 stood at $88785.0 (up 127.77% YoY), while the FY2025 annual figure was $88785.0, up 127.77% from the prior year.
- Other Working Capital Changes declined to -$6178.0 in Q3 2016 per RLMD's latest filing, from $31929.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $1.0 million in Q3 2024 and bottomed at -$1.7 million in Q4 2023.
- Historically, Other Working Capital Changes has averaged -$209392.3 across 3 years, with a median of -$204312.0 in 2024.
- On a YoY basis, Other Working Capital Changes climbed as much as 101.07% in 2025 and fell as far as 51.45% in 2025.
- Relmada Therapeutics' Other Working Capital Changes stood at -$1.7 million in 2023, then surged by 57.77% to -$698342.0 in 2024, then surged by 101.07% to $7500.0 in 2025.
- Business Quant data shows RLMD's Other Working Capital Changes at $7500.0 in Q4 2025, $493119.0 in Q3 2025, and -$121783.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 7,500.00 |
| Dec 31, 2025 | 7,500.00 |
| Sep 30, 2025 | 493,119.00 |
| Sep 30, 2025 | 493,119.00 |
| Jun 30, 2025 | -121,783.00 |
| Jun 30, 2025 | -121,783.00 |
| Mar 31, 2025 | -290,051.00 |
| Mar 31, 2025 | -290,051.00 |
| Dec 31, 2024 | -698,342.00 |
| Dec 31, 2024 | -698,342.00 |
| Sep 30, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | -204,312.00 |
| Jun 30, 2024 | -204,312.00 |
| Mar 31, 2024 | -432,723.00 |
| Mar 31, 2024 | -432,723.00 |
| Dec 31, 2023 | -1.65 Mn |
| Dec 31, 2023 | -1.65 Mn |
| Sep 30, 2016 | -6,178.00 |
| Sep 30, 2016 | -6,178.00 |